Performance of 18F-FDG PET/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer

Tianhang Li; Qinqin You; Shiwei Zhang; Rushuai Li; Shangxun Xie; Danyan Li; Shuyue Ai; Rong Yang; Hongqian Guo

doi:10.1016/j.isci.2024.109657

Performance of ¹⁸F-FDG PET/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer

iScience. 2024 Apr 3;27(5):109657. doi: 10.1016/j.isci.2024.109657. eCollection 2024 May 17.

Authors

Tianhang Li^{1

2

3}, Qinqin You⁴, Shiwei Zhang¹, Rushuai Li⁴, Shangxun Xie¹, Danyan Li⁵, Shuyue Ai⁴, Rong Yang¹, Hongqian Guo¹

Affiliations

¹ Department of Urology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
² Department of Urology, Zhongda Hospital, Southeast University, Nanjing, China.
³ Surgical Research Center, Institute of Urology, Southeast University Medical School, Nanjing, China.
⁴ Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
⁵ Department of Radiology, Nanjing Drum Tower Hospital, Affiliated Medical School of Nanjing University, Nanjing, China.

Abstract

¹⁸F-FDG PET/MRI shows potential efficacy in the diagnosis of bladder cancer (BLCA). However, the performance of ¹⁸F-FDG PET/MRI in staging and neoadjuvant therapy (NAT) response evaluation for BLCA patients remains elusive. Here, we conduct this study to evaluate the performance of ¹⁸F-FDG PET/MRI and its derived parameters for tumor staging and NAT response prediction in BLCA. Forty BLCA patients were retrospectively enrolled to evaluate the performance of ¹⁸F-FDG PET/MRI in staging and NAT response prediction in BLCA. The feasibility of using 18F-FDG PET/MRI-related parameters for tumor staging and NAT response evaluation was also analyzed. In conclusion, ¹⁸F-FDG PET/MRI is found to show good performance in the BLCA staging and NAT response prediction. Moreover, ΔSUVmean is an efficacious candidate parameter for NAT response prediction. This study highlights that ¹⁸F-FDG PET/MRI is a promising imaging approach in the clinical diagnosis and treatment for BLCA.

Keywords: Clinical finding; Oncology.